Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 20/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 13/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 15/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117954 | 1.00 | ADRB3 (0.66) | ADRB3ADRB1ADRB2ADRA2AADRA2B | |
| SCHEMBL6800160 | 0.97 | ADRB3 (0.65) | ADRB3ADRB1ADRB2ADRA2AADRA2B | |
| SCHEMBL6800153 | 0.97 | ADRB3 (0.65) | ADRB3ADRB1ADRB2ADRA2AADRA2B | |
| SCHEMBL6801388 | 0.91 | ADRB3 (0.57) | ADRB3ADRB1ADRB2ADRA2AADRA2B | |
| SCHEMBL6801390 | 0.91 | ADRB3 (0.57) | ADRB3ADRB1ADRB2ADRA2AADRA2B | |
| SCHEMBL6798028 | 0.89 | ADRB3 (0.75) | ADRB3ADRB1ADRB2ADRA2AADRA2B | |
| SCHEMBL6798002 | 0.89 | ADRB3 (0.75) | ADRB3ADRB1ADRB2ADRA2AADRA2B | |
| SCHEMBL6802958 | 0.87 | ADRB3 (0.67) | ADRB3ADRB1ADRB2ADRA2AADRA2B | |
| SCHEMBL6802964 | 0.87 | ADRB3 (0.67) | ADRB3ADRB1ADRB2ADRA2AADRA2B | |
| SCHEMBL6800475 | 0.86 | ADRB3 (0.69) | ADRB3ADRB1ADRB2ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB1 2/4885ADRB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.